AAAAAA

   
Results: 1-15 |
Results: 15
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate (vol 6, pg 3493, 2000)
Authors: Krug, LM Ng, KK Kris, MG Miller, VA Tong, W Heelan, RT Leon, L Leung, D Kelly, J Sirotnak, FM
Citation: Lm. Krug et al., Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate (vol 6, pg 3493, 2000), CLIN CANC R, 7(4), 2001, pp. 1102-1102
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate
Authors: Krug, LM Ng, KK Kris, MG Miller, VA Tong, W Heelan, RT Leon, L Leung, D Kelly, J Sirotnak, FM
Citation: Lm. Krug et al., Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate, CLIN CANC R, 6(9), 2000, pp. 3493-3498
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo
Authors: Sirotnak, FM Wendel, HG Bornmann, WGB Tong, WP Miller, VA Scher, HI Kris, MG
Citation: Fm. Sirotnak et al., Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo, CLIN CANC R, 6(9), 2000, pp. 3705-3712
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)
Authors: Soignet, SL Miller, VA Pfister, DG Bienvenu, BJ Ho, R Parker, BA Amyotte, SA Cato, A Warrell, RP
Citation: Sl. Soignet et al., Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550), CLIN CANC R, 6(5), 2000, pp. 1731-1735
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
Authors: Sirotnak, FM Zakowski, MF Miller, VA Scher, HI Kris, MG
Citation: Fm. Sirotnak et al., Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, CLIN CANC R, 6(12), 2000, pp. 4885-4892
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
Authors: Krug, LM Miller, VA Kalemkerian, GP Kraut, MJ Ng, KK Heelan, RT Pizzo, BA Perez, W McClean, N Kris, MG
Citation: Lm. Krug et al., Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer, ANN ONCOL, 11(2), 2000, pp. 227-228
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
Authors: Miller, VA Krug, LM Ng, KK Pizzo, B Perez, W Heelan, RT Kris, MG
Citation: Va. Miller et al., Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer, J CL ONCOL, 18(6), 2000, pp. 1346-1350
Docetaxel (Taxotere) as a single agent and in combination chemotherapy forthe treatment of patients with advanced non-small cell lung cancer
Authors: Miller, VA Kris, MG
Citation: Va. Miller et Mg. Kris, Docetaxel (Taxotere) as a single agent and in combination chemotherapy forthe treatment of patients with advanced non-small cell lung cancer, SEMIN ONCOL, 27(2), 2000, pp. 3-10
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma
Authors: Miller, VA Ng, KK Krug, LM Perez, W Pizzo, B Heelen, RT Kris, MG
Citation: Va. Miller et al., Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma, CANCER, 88(5), 2000, pp. 1045-1050
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer
Authors: Dickler, MN Ragupathi, G Liu, NX Musselli, C Martino, DJ Miller, VA Kris, MG Brezicka, FT Livingston, PO Grant, SC
Citation: Mn. Dickler et al., Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer, CLIN CANC R, 5(10), 1999, pp. 2773-2779
Oral cisapride for the control of delayed vomiting following high-dose cisplatin
Authors: Pizzo, BA Pisters, KMW Miller, VA Grant, SC Baltzer, L Hinckley, L Kris, MG
Citation: Ba. Pizzo et al., Oral cisapride for the control of delayed vomiting following high-dose cisplatin, SUPP CARE C, 7(1), 1999, pp. 44-46
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors
Authors: Rigas, JR Kris, MG Miller, VA Pisters, KMW Heelan, RT Grant, SC Fennelly, DW Chou, TC Sirotnak, FM
Citation: Jr. Rigas et al., Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors, ANN ONCOL, 10(5), 1999, pp. 601-603
Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer
Authors: Krug, LM Miller, VA
Citation: Lm. Krug et Va. Miller, Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer, SEMIN ONCOL, 26(5), 1999, pp. 24-26
Strategies to eradicate minimal residual disease in small cell lung cancer: High-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination
Authors: Krug, LM Grant, SC Miller, VA Ng, KK Kris, MG
Citation: Lm. Krug et al., Strategies to eradicate minimal residual disease in small cell lung cancer: High-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination, SEMIN ONCOL, 26(5), 1999, pp. 55-61
Induction chemotherapy employing dose-intense cisplatin with mitomycin andvinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma
Authors: Ng, KK Kris, MG Ginsberg, RJ Heelan, RT Pisters, KMW Miller, VA Grant, SG Bains, M Rusch, V Rosenzweig, KE Martini, N
Citation: Kk. Ng et al., Induction chemotherapy employing dose-intense cisplatin with mitomycin andvinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma, CANCER, 86(7), 1999, pp. 1189-1197
Risultati: 1-15 |